VABYSMO 6MG / 0.05ML SOLUTION FOR INJECTION
FARICIMAB
What it does
Faricimab is a medication used to treat certain eye conditions that can cause vision loss.
Commonly used for: diabetic macular edema (swelling in the eye due to diabetes), wet age-related macular degeneration (a type of vision loss in older adults)
Read more in plain English ↓Plain-language summary for general understanding - not medical advice. Always follow your pharmacist/doctor.
Ask about this medicine
Answers come only from this medicine's registration record, BNF monograph and interaction data - not medical advice.
Hard to find? We help patients in Kenya source rare medicines. We don't sell or dispense medicines - licensed pharmacies do.
Source this medicineRegistration & product details
Source: Pharmacy and Poisons Board · fetched 2026-06-28 19:42:54 · updated 2026-10-30 02:05:44
About this medicine
Faricimab is a medication used to treat certain eye conditions that can cause vision loss.
What it treats
- diabetic macular edema (swelling in the eye due to diabetes)
- wet age-related macular degeneration (a type of vision loss in older adults)
How it works
Faricimab works by targeting specific proteins in the eye to reduce swelling and improve vision.
Who it's for
This medication is for adults with specific eye conditions that lead to vision problems.
AI-assisted summary grounded in BNF data - general information only, not medical advice. Always confirm with your pharmacist or doctor.
Clinical monograph: Faricimab
BNF-referencedFaricimab is a bispecific immunoglobulin G1 antibody that acts as a dual inhibitor of angiopoietin-2 and vascular endothelial growth factor (VEGF), promoting vascular stability and reducing pathological angiogenesis. It is primarily used in the treatment of retinal disorders, particularly neovascular (wet) age-related macular degeneration (wAMD) and diabetic macular oedema (DMO).
Indications
- Neovascular (wet) age-related macular degeneration
- Diabetic macular oedema
Dosage
Children: There are no established pediatric dosing guidelines for Faricimab. For dosing in children, please refer to the BNF for Children.
Adults: The dosage for adults is determined by a specialist and varies based on the specific condition being treated. Please refer to the BNF for precise dosing guidelines.
Mechanism of action
Faricimab targets and inhibits both angiopoietin-2 (Ang-2) and vascular endothelial growth factor A (VEGF-A), which are key mediators in the regulation of vascular permeability and angiogenesis. By blocking these pathways, Faricimab restores vascular stability in the retina, thereby reducing edema and preventing vision loss associated with retinal diseases.
Pharmacodynamics
The pharmacodynamic effects of Faricimab include the reduction of retinal vascular leakage and the inhibition of neovascularization. The dual inhibition of Ang-2 and VEGF-A leads to improved retinal perfusion and stabilization of the retinal architecture, which is crucial in conditions characterized by abnormal blood vessel growth and leakage.
Pharmacokinetics
Faricimab is administered via intravitreal injection, allowing for direct delivery to the target site in the eye. Its pharmacokinetic profile shows a prolonged half-life due to its large molecular size and is characterized by a gradual clearance from the vitreous. Systemic absorption is minimal, leading to low systemic exposure. The drug is primarily eliminated through the reticuloendothelial system.
Contra-indications
- Active intra-ocular inflammation
- Ocular or periocular infection
- Rhegmatogenous retinal detachment
- Retinal tear
- Stage 3 or 4 macular holes
Adverse effects
- Endophthalmitis
- Intra-ocular inflammation
- Visual impairment
- Retinal detachment
Precautions
- Monitor intra-ocular pressure and perfusion of the optic nerve head following injection
- Counsel patients to report symptoms suggestive of endophthalmitis or retinal detachment
Pregnancy
Avoid unless potential benefit outweighs risk; systemic exposure is very low.
Breast-feeding
Use with caution; limited excretion into milk expected and likely partially destroyed in the infant's gastrointestinal tract.
Storage
Store in a refrigerator (2–8°C); may be stored unopened at room temperature (20–25°C) for up to 24 hours before use; protect from light.
Formulations
- Solution for injection (Brolucizumab 120 mg per 1 ml)
- Solution for injection (Vabysmo)
AI-synthesized from BNF references - general information only, not a substitute for professional medical advice or the current BNF. Verify doses with a pharmacist.
This drug in other countries
The same active ingredient registered across other registries we cover - including different brands.